Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asunaprevir/beclabuvir/daclatasvir - Bristol-Myers Squibb

Drug Profile

Asunaprevir/beclabuvir/daclatasvir - Bristol-Myers Squibb

Alternative Names: Asunaprevir/daclatasvir/BMS 791325; BMS 791325/asunaprevir/daclatasvir; Daclatasvir/BMS 791325/asunaprevir; DCV 3DAA FDC; DCV-TRIO; DCV/ASV/BMS-791325; Ximency

Latest Information Update: 09 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Amides; Azabicyclo compounds; Benzazepines; Biphenyl compounds; Carbamates; Cyclohexanes; Cyclopropanes; Heterocyclic compounds with 4 or more rings; Imidazoles; Indoles; Isoquinolines; Organic bridged compounds; Phenyl ethers; Piperazines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2017 Toranomon Hospital initiates enrolment in a clinical trial for Hepatitis-C in Japan (UMIN000026909)
  • 20 Feb 2017 Bristol-Myers Squibb initiates enrolment in an observational, postmarketing commitment study for Hepatitis C in Japan (NCT03071133)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top